Journal Club: Cardiovascular Morbidity Associated with Gonadotropin Releasing Hormones Agonist and an Antagonist
September 27, 2016
The hypothesis and approach for this article includes a discussion around if a GnRH antagonist produce the same risk of cardiovascular complication when compared to an LHRH agonist. Also, the data from six, phase 3, randomized trials conducted by Ferring Pharmaceuticals to test the efficacy of a new GnRH antagonist. The data analyzed independently by a statistician at the University of Connecticut funded by a grant from the “V” Foundation.
Read the Abstract
Thomas E. Keane, MBBCh, FRCSI, FACS, is Professor and Chairman of the Department of Urology at the Medical University of South Carolina in Charleston. Dr. Keane specializes in managing prostate, bladder, and renal cancers.
An avid researcher, Dr. Keane has served as principal investigator or coinvestigator on more than 20 major clinical and preclinical studies, funded by grants from the National Institutes of Health as well as industry-funded. Much of his work focuses on innovative concepts in translational research, including utilizing human tumor xenografts to investigate the efficacy of new therapies as they relate to GU malignancies with particular reference to cytotoxic agents, sphingolipids, and boron-containing compounds. He holds a U.S. patent for sphingolipid derivatives and their use